Skip to main content
. 2023 Feb 12;15(4):1177. doi: 10.3390/cancers15041177

Figure 2.

Figure 2

Overview of treatment in NPM1mut-AML; (FLT3i- FLT3 inhibitor; CR- complete response; ASCT-allogenic stem cell transplant; HMA- hypomethylating agents, £- pending clinical validation).